Saturday 17 October 2026
Export IMNN’s income statement to Excel — free account
Imunon, Inc.
IMNN Healthcare Biotechnology
Imunon, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $500,000.00. In the quarter to June 2026, EPS grew 71.1% and free cash flow fell 4.24%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.02
0.04
−3.77%
Follow IMNN
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Piotroski F-Score |
3 | 5 | 3 | 2 | 4 | 3 | 2 | — | — | — |
P/S ratio |
16.65 | 43.04 | 49.66 | 74.74 | 45.40 | 87.96 | 21.44 | — | — | — |
Altman Z-Score |
(13.10) | (7.94) | (8.51) | (11.18) | (12.15) | (5.04) | (12.47) | — | — | — |
Altman Z″-Score (non-manufacturers) |
(30.54) | (16.72) | (18.14) | (26.28) | (27.27) | (9.34) | (25.05) | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Beneish M-Score |
— | 8.75 | — | (2.57) | — | — | — | — | — | — |
P/Operating CF |
(1.79) | (5.11) | 4.08 | (6.65) | (6.08) | (8.64) | (2.14) | — | — | — |
P/B ratio |
1.24 | 0.81 | 1.19 | 2.57 | 1.22 | 0.79 | 0.37 | — | — | — |
Price to Tangible BV |
2.23 | 0.90 | 1.36 | 3.05 | 1.37 | 0.82 | 0.39 | — | — | — |
EV/Sales |
10.68 | (2.66) | 13.27 | 60.95 | 18.94 | 0.89 | (37.83) | — | — | — |
EV/EBITDA |
0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.79 | — | — | — |
EV/Operating CF |
(0.29) | 0.08 | (0.94) | (1.50) | (0.61) | (0.03) | 0.82 | — | — | — |
EV/FCF |
(0.29) | 0.08 | (0.92) | (1.48) | (0.61) | (0.03) | 0.81 | — | — | — |
Quick Ratio |
0.51 | 3.91 | 4.52 | 1.88 | 2.54 | 7.30 | 3.41 | 2.12 | 1.23 | 1.90 |
Current Ratio |
0.54 | 3.92 | 4.61 | 2.06 | 2.79 | 7.67 | 3.66 | 2.47 | 1.67 | 2.32 |
Net Debt/EBITDA |
0.22 | 1.35 | 0.89 | 0.35 | 0.76 | 2.17 | 1.23 | 0.77 | 0.32 | 0.63 |
Debt/Assets |
0.00% | 0.00% | 20.10% | 20.80% | 10.48% | 7.91% | 10.49% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.45 | 0.55 | 0.21 | 0.10 | 0.16 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.83 | 0.80 | 0.59 | 1.20 | 0.73 | 0.78 | 0.64 | 0.97 | 1.01 | 0.96 |
Capex/Depreciation |
(0.05) | (0.07) | (0.25) | (0.32) | (0.02) | (0.33) | (0.29) | (0.58) | (0.04) | (0.40) |
Interest Coverage |
(28.56) | (201.18) | (29.59) | (14.76) | (14.30) | (36.86) | (4.96) | (106.70) | — | — |
| (162.69%) | (124.13%) | (49.97%) | (95.15%) | (129.54%) | (55.83%) | (84.34%) | (91.37%) | (211.21%) | (256.41%) | |
| (55.22%) | (52.95%) | (25.18%) | (39.59%) | (56.68%) | (37.23%) | (60.83%) | (59.23%) | (117.72%) | (131.74%) | |
ROIC |
(532.96%) | (455.08%) | (493.72%) | (167.77%) | (214.70%) | (107.08%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
639.63% | (113.45%) | (53.51%) | (192.67%) | (173.73%) | (45.49%) | (131.54%) | (168.21%) | (494.67%) | (218.63%) |
Average Days of Receivables |
2.92 | 39.71 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
2,924.62% | 2,615.74% | 2,373.10% | 2,613.06% | 2,268.96% | 2,123.86% | 2,346.74% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
1,305.36% | 1,177.94% | 1,939.90% | 1,600.04% | 1,528.32% | 2,177.58% | 2,737.58% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.10 | 0.06 | 0.05 | 0.06 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
302.20% | 221.04% | 926.86% | 458.34% | 370.28% | 751.94% | 534.60% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
(2.36) | 0.16 | 0.09 | (0.20) | 0.00 | 0.77 | 2.06 | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Earnings Yield |
(265.47%) | (96.47%) | (46.05%) | (44.90%) | (94.27%) | (46.12%) | (344.41%) | — | — | — |
Free Cash Flow Yield |
(221.47%) | (77.52%) | (28.92%) | (55.14%) | (68.90%) | (37.60%) | (217.91%) | — | — | — |
Revenue per Share |
52.63 | 12.82 | 5.56 | 4.48 | 3.06 | 1.20 | 0.91 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1,934.67) | (426.72) | (78.24) | (181.37) | (95.59) | (38.97) | (42.16) | (27.42) | (17.16) | (6.54) |
Capex per Share |
(6.58) | (0.99) | (1.54) | (3.13) | (0.12) | (0.75) | (0.49) | (0.65) | (0.03) | (0.13) |
Free Cash Flow per Share |
(1,941.25) | (427.71) | (79.78) | (184.50) | (95.70) | (39.72) | (42.64) | (28.07) | (17.18) | (6.68) |
Cash per Share |
453.07 | 619.69 | 306.79 | 133.05 | 105.04 | 118.64 | 62.51 | 22.62 | 5.34 | 4.14 |
Shareholders Equity per Share |
707.98 | 684.73 | 231.79 | 130.34 | 113.90 | 134.03 | 53.53 | 19.30 | 3.86 | 3.33 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
707.98 | 684.73 | 231.79 | 130.34 | 113.90 | 134.03 | 53.53 | 19.30 | 3.86 | 3.33 |
Free Cash Flow |
(18.44) | (16.68) | (7.18) | (20.61) | (15.64) | (16.54) | (23.36) | (19.47) | (18.88) | (14.18) |
Working Capital |
(3.91) | 18.11 | 22.02 | 8.34 | 12.07 | 45.18 | 26.74 | 10.85 | 3.22 | 6.10 |
Capital Expenditures |
(0.06) | (0.04) | (0.14) | (0.35) | (0.02) | (0.31) | (0.27) | (0.45) | (0.03) | (0.28) |
Net Current Asset Value |
(19.61) | 3.50 | 2.14 | (7.48) | (0.09) | 33.69 | 22.13 | 9.71 | 2.54 | 5.50 |
EV/EBIT |
0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.76 | — | — | — |
Capex to Sales |
0.13 | 0.08 | 0.28 | 0.70 | 0.04 | 0.62 | 0.54 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
2.73 | 3.35 | 3.01 | 2.73 | 4.04 | 1.97 | 1.67 | 1.03 | 1.33 | 1.32 |
Cash ROIC |
(167.20%) | (32.79%) | (12.40%) | (55.13%) | (39.38%) | (14.89%) | (34.27%) | (66.96%) | (186.66%) | (89.49%) |
Accounts Receivable Turnover |
8.27 | 17.12 | 8.15 | 11.15 | 0.00 | 7.68 | 4.21 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.06 | 0.03 | 0.06 | 0.04 | — | 0.07 | 0.12 | — | — | — |
Average Payables |
2.85 | 3.15 | 3.22 | 2.94 | 2.55 | 2.40 | 3.07 | 3.55 | 2.41 | 1.35 |
Average Assets |
39.94 | 39.18 | 47.19 | 42.57 | 37.90 | 55.79 | 59.01 | 32.95 | 15.82 | 11.00 |
Average Common Equity |
13.56 | 16.72 | 23.78 | 17.71 | 16.59 | 37.20 | 42.56 | 21.36 | 8.82 | 5.65 |
Columns are period end dates